The contribution of cervicovaginal infections to the immunomodulatory effects of hormonal contraception

mBio

Volumn 6, Issue 5, 2015, Pages

  Fichorova, Raina N ^a   Chen, Pai Lien ^b   Morrison, Charles S ^b   Doncel, Gustavo F ^c   Mendonca, Kevin ^a   Kwok, Cynthia ^b   Chipato, Tsungai ^d   Salata, Robert ^e   Mauck, Christine ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b FAMILY HEALTH INTERNATIONAL   (United States)

^c EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEFENSIN 2; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR ANTIGEN; INTERLEUKIN 1BETA; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; RANTES; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; MEDROXYPROGESTERONE;

ADULT; ARTICLE; CANDIDIASIS; CHLAMYDIA; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SAFETY; FEMALE; GONORRHEA; HORMONAL CONTRACEPTION; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MUCOSAL IMMUNITY; PREGNANT WOMAN; PRIORITY JOURNAL; TRICHOMONIASIS; UTERINE CERVICITIS; WOMEN'S HEALTH; ADOLESCENT; DISEASE PREDISPOSITION; GENITAL TRACT INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; TRANSMISSION; UGANDA; YOUNG ADULT; ZIMBABWE;

ADOLESCENT; ADULT; CONTRACEPTIVES, ORAL, HORMONAL; DISEASE SUSCEPTIBILITY; HIV INFECTIONS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; MEDROXYPROGESTERONE; REPRODUCTIVE TRACT INFECTIONS; UGANDA; YOUNG ADULT; ZIMBABWE;

EID: 84946606170     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00221-15     Document Type: Article

References (79)

1. Morrison CS, Chen PL, Kwok C, Richardson BA, Chipato T, Mugerwa R, Byamugisha J, Padian N, Celentano DD, Salata RA. 2010. Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. AIDS 24:1778-1781. http://dx.doi.org/10.1097/QAD.0b013e32833a2537.
2. Morrison CS, Turner AN, Jones LB. 2009. Highly effective contraception and acquisition of HIV and other sexually transmitted infections. Best Pract Res Clin Obstet Gynaecol 23:263-284. http://dx.doi.org/10.1016/j.bpobgyn.2008.11.004.
3. Mugo NR, Heffron R, Donnell D, Wald A, Were EO, Rees H, Celum C, Kiarie JN, Cohen CR, Kayintekore K, Baeten JM, Partners in Prevention HSV/HIV Transmission Study Team. 2011. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS 25:1887-1895. http://dx.doi.org/10.1097/QAD.0b013e32834a9338.
4. Gray RH, Li X, Kigozi G, Serwadda D, Brahmbhatt H, Wabwire-Mangen F, Nalugoda F, Kiddugavu M, Sewankambo N, Quinn TC, Reynolds SJ, Wawer MJ. 2005. Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet 366:1182-1188. http://dx.doi.org/10.1016/S0140-6736(05)67481-8.
5. Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, de Bruyn G, Nakku-Joloba E, Ngure K, Kiarie J, Coombs RW, Baeten JM, Partners in Prevention HSV/HIV Transmission Study Team. 2012. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 12:19-26. http://dx.doi.org/10.1016/S1473-3099(11)70247-X.
6. Baeten JM, Nyange PM, Richardson BA, Lavreys L, Chohan B, Martin HL, Mandaliya K, Ndinya-Achola JO, Bwayo JJ, Kreiss JK. 2001. Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol 185:380-385. http://dx.doi.org/10.1067/mob.2001.115862.
7. Morrison CS, Richardson BA, Mmiro F, Chipato T, Celentano DD, Luoto J, Mugerwa R, Padian N, Rugpao S, Brown JM, Cornelisse P, Salata RA, Hormonal Contraception and the Risk of HIV Acquisition (HC-HIV) Study Group. 2007. Hormonal contraception and the risk of HIVacquisition. AIDS 21:85-95. http://dx.doi.org/10.1097/QAD.0b013e3280117c8b.
8. Lekovich JP, Amrane S, Pangasa M, Pereira N, Frey MK, Varrey A, Holcomb K. 2015. Comparison of human papillomavirus infection and cervical cytology in women using copper-containing and levonorgestrelcontaining intrauterine devices. Obstet Gynecol 125:1101-1105. http://dx.doi.org/10.1097/AOG.0000000000000760.
9. United Nations. 2011. World contraceptive use. Department of Economic and Social Affairs, Population Division, United Nations, New York, NY.
10. Masson L, Passmore JS, Liebenberg LJ, Werner L, Baxter C, Arnold KB, Williamson C, Little F, Mansoor LE, Naranbhai V, Lauffenburger DA, Ronacher K, Walzl G, Garrett NJ, Williams BL, Couto-Rodriguez M, Hornig M, Lipkin WI, Grobler A, Abdool Karim Q. 2015. Genital inflammation and the risk of HIV acquisition in women. Clin Infect Dis 61:260-269. http://dx.doi.org/10.1093/cid/civ298.
11. Fichorova RN, Anderson DJ. 1999. Differential expression of immunobiological mediators by immortalized human cervical and vaginal epithelial cells. Biol Reprod 60:508-514. http://dx.doi.org/10.1095/ biolreprod60.2.508.
12. Fichorova RN, Rheinwald JG, Anderson DJ. 1997. Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical, and vaginal epithelium that maintain expression of tissuespecific differentiation proteins. Biol Reprod 57:847-855. http://dx.doi.org/10.1095/biolreprod57.4.847.
13. Wira CR, Grant-Tschudy KS, Crane-Godreau MA. 2005. Epithelial cells in the female reproductive tract: a central role as sentinels of immune protection. Am J Reprod Immunol 53:65-76. http://dx.doi.org/10.1111/j.1600-0897.2004.00248.x.
14. Alfano M, Poli G. 2002. The cytokine network in HIV infection. Curr Mol Med 2:677-689. http://dx.doi.org/10.2174/1566524023361925.
15. Kyongo JK, Jespers V, Goovaerts O, Michiels J, Menten J, Fichorova RN, Crucitti T, Vanham G, Ariën KK. 2012. Searching for lower female genital tract soluble and cellular biomarkers: defining levels and predictors in a cohort of healthy Caucasian women. PLoS One 7:e43951. http://dx.doi.org/10.1371/journal.pone.0043951.
16. Al-Harthi L, Kovacs A, Coombs RW, Reichelderfer PS, Wright DJ, Cohen MH, Cohn J, Cu-Uvin S, Watts H, Lewis S, Beckner S, Landay A, WHS 001 Study Team. 2001. A menstrual cycle pattern for cytokine levels exists in HIV-positive women: implication for HIV vaginal and plasma shedding. AIDS 15:1535-1543. http://dx.doi.org/10.1097/ 00002030-200108170-00011.
17. Al-Harthi L, Wright DJ, Anderson D, Cohen M, Matity Ahu D, Cohn J, Cu-Unvin S, Burns D, Reichelderfer P, Lewis S, Beckner S, Kovacs A, Landay A. 2000. The impact of the ovulatory cycle on cytokine production: evaluation of systemic, cervicovaginal, and salivary compartments. J Interferon Cytokine Res 20:719-724. http://dx.doi.org/10.1089/10799900050116426.
18. Wira CR, Fahey JV. 2008. A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. AIDS 22:1909-1917. http://dx.doi.org/10.1097/QAD.0b013e3283060ea4.
19. Gargiulo AR, Fichorova RN, Politch JA, Hill JA, Anderson DJ. 2004. Detection of implantation-related cytokines in cervicovaginal secretions and peripheral blood of fertile women during ovulatory menstrual cycles. Fertil Steril 82(Suppl 3):1226-1234. http://dx.doi.org/10.1016/ j.fertnstert.2004.03.039.
20. Fleming DC, King AE, Williams AR, Critchley HO, Kelly RW. 2003. Hormonal contraception can suppress natural antimicrobial gene transcription in human endometrium. Fertil Steril 79:856-863. http://dx.doi.org/10.1016/S0015-0282(02)04930-0.
21. Barousse MM, Theall KP, Van Der Pol B, Fortenberry JD, Orr DP, Fidel PL. 2007. Susceptibility of middle adolescent females to sexually transmitted infections: impact of hormone contraception and sexual behaviors on vaginal immunity. Am J Reprod Immunol 58:159-168. http://dx.doi.org/10.1111/j.1600-0897.2007.00504.x.
22. Morrison C, Fichorova RN, Mauck C, Chen PL, Kwok C, Chipato T, Salata R, Doncel GF. 2014. Cervical inflammation and immunity associated with hormonal contraception, pregnancy, and HIV-1 seroconversion. J Acquir Immune Defic Syndr 66:109-117. http://dx.doi.org/10.1097/QAI.0000000000000103.
23. Goldfien GA, Barragan F, Chen J, Takeda M, Irwin JC, Perry J, Greenblatt RM, Smith-McCune KK, Giudice LC. 2015. Progestin-containing contraceptives alter expression of host defense-related genes of the endometrium and cervix. Reprod Sci 22:814-828. http://dx.doi.org/10.1177/1933719114565035.
24. Huijbregts RP, Helton ES, Michel KG, Sabbaj S, Richter HE, Goepfert PA, Hel Z. 2013. Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms. Endocrinology 154:1282-1295. http://dx.doi.org/10.1210/en.2012-1850.
25. Guthrie BL, Introini A, Roxby AC, Choi RY, Bosire R, Lohman-Payne B, Hirbod T, Farquhar C, Broliden K. 2015. Depot medroxyprogesterone acetate use is associated with elevated innate immune effector molecules in cervicovaginal secretions of HIV-1-uninfected women. J Acquir Immune Defic Syndr 69:1-10. http://dx.doi.org/ 10.1097/QAI.0000000000000533.
26. Mauck CK, Chen P, Morrison C, Fichorova R, Kwok C, Chipato T, Salata R, Doncel G. 2014. Biomarkers of cervical inflammation and immunity associated with cervical HIV-1 RNA. AIDS Res Hum Retroviruses 30(Suppl 1):A181. http://dx.doi.org/10.1089/aid.2014.5386.abstract.
27. Mitchell C, Marrazzo J. 2014. Bacterial vaginosis and the cervicovaginal immune response. Am J Reprod Immunol 71:555-563. http://dx.doi.org/ 10.1111/aji.12264.
28. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. 2006. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20:73-83. http://dx.doi.org/10.1097/01.aids.0000198081.09337.a7.
29. Laga M, Manoka A, Kivuvu M, Malele B, Tuliza M, Nzila N, Goeman J, Behets F, Batter V, Alary M, et al. 1993. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 7:95-102. http://dx.doi.org/10.1097/00002030-199301000-00015.
30. Masson L, Mlisana K, Little F, Werner L, Mkhize NN, Ronacher K, Gamieldien H, Williamson C, Mckinnon LR, Walzl G, Abdool Karim Q, Abdool Karim SS, Passmore JA. 2014. Defining genital tract cytokine signatures of sexually transmitted infections and bacterial vaginosis in women at high risk of HIV infection: a cross-sectional study. Sex Transm Infect 90:580-587. http://dx.doi.org/10.1136/sextrans-2014-051601.
31. Anahtar MN, Byrne EH, Doherty KE, Bowman BA, Yamamoto HS, Soumillon M, Padavattan N, Ismail N, Moodley A, Sabatini ME, Ghebremichael MS, Nusbaum C, Huttenhower C, Virgin HW, Ndung’u T, Dong KL, Walker BD, Fichorova RN, Kwon DS. 2015. Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity 42:965-976. http://dx.doi.org/10.1016/ j.immuni.2015.04.019.
32. van de Wijgert JH, Mason PR, Gwanzura L, Mbizvo MT, Chirenje ZM, Iliff V, Shiboski S, Padian NS. 2000. Intravaginal practices, vaginal flora disturbances, and acquisition of sexually transmitted diseases in Zimbabwean women. J Infect Dis 181:587-594. http://dx.doi.org/10.1086/315227.
33. van de Wijgert JH, Morrison CS, Brown J, Kwok C, Van Der Pol B, Chipato T, Byamugisha JK, Padian N, Salata RA. 2009. Disentangling contributions of reproductive tract infections to HIV acquisition in African women. Sex Transm Dis 36:357-364. http://dx.doi.org/10.1097/OLQ.0b013e3181a4f695.
34. Brown JM, Wald A, Hubbard A, Rungruengthanakit K, Chipato T, Rugpao S, Mmiro F, Celentano DD, Salata RS, Morrison CS, Richardson BA, Padian NS. 2007. Incident and prevalent herpes simplex virus type 2 infection increases risk of HIV acquisition among women in Uganda and Zimbabwe. AIDS 21:1515-1523. http://dx.doi.org/10.1097/QAD.0b013e3282004929.
35. Buve A, Jespers V, Crucitti T, Fichorova RN. 2014. The vaginal microbiota and susceptibility to HIV. AIDS 28:2333-2344. http://dx.doi.org/10.1097/QAD.0000000000000432.
36. Fichorova RN. 2004. Guiding the vaginal microbicide trials with biomarkers of inflammation. J Acquir Immune Defic Syndr 37(Suppl 3): S184-S193. http://dx.doi.org/10.1097/00126334-200410013-00010.
37. Fichorova RN, Lai JJ, Schwartz JL, Weiner DH, Mauck CK, Callahan MM. 2011. Baseline variation and associations between subject characteristics and five cytokine biomarkers of vaginal safety among healthy nonpregnant women in microbicide trials. Cytokine 55:134-140. http://dx.doi.org/10.1016/j.cyto.2011.03.016.
38. Anderson DJ, Politch JA, Tucker LD, Fichorova R, Haimovici F, Tuomala RE, Mayer KH. 1998. Quantitation of mediators of inflammation and immunity in genital tract secretions and their relevance to HIV type 1 transmission. AIDS Res Hum Retroviruses 14(Suppl 1):S43-S49.
39. Fichorova RN, Bajpai M, Chandra N, Hsiu JG, Spangler M, Ratnam V, Doncel GF. 2004. Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol Reprod 71:761-769. http://dx.doi.org/10.1095/biolreprod.104.029603.
40. Fichorova RN, Desai PJ, Gibson FC, Genco CA. 2001. Distinct proinflammatory host responses to Neisseria gonorrhoeae infection in immortalized human cervical and vaginal epithelial cells. Infect Immun 69: 5840-5848. http://dx.doi.org/10.1128/IAI.69.9.5840-5848.2001.
41. Fichorova RN, Lee Y, Yamamoto HS, Takagi Y, Hayes GR, Goodman RP, Chepa-Lotrea X, Buck OR, Murray R, Kula T, Beach DH, Singh BN, Nibert ML. 2012. Endobiont viruses sensed by the human host— beyond conventional antiparasitic therapy. PLoS One 7:e48418. http://dx.doi.org/10.1371/journal.pone.0048418.
42. Fichorova RN, Tucker LD, Anderson DJ. 2001. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis 184: 418-428. http://dx.doi.org/10.1086/322047.
43. Fichorova RN, Yamamoto HS, Delaney ML, Onderdonk AB, Doncel GF. 2011. Novel vaginal microflora colonization model providing new insight into microbicide mechanism of action. mBio 2(6):e00168-11. http://dx.doi.org/10.1128/mBio.00168-11.
44. Fichorova RN, Trifonova RT, Gilbert RO, Costello CE, Hayes GR, Lucas JJ, Singh BN. 2006. Trichomonas vaginalis lipophosphoglycan triggers a selective upregulation of cytokines by human female reproductive tract epithelial cells. Infect Immun 74:5773-5779. http://dx.doi.org/10.1128/IAI.00631-06.
45. Mauck CK, Ballagh SA, Creinin MD, Weiner DH, Doncel GF, Fichorova RN, Schwartz JL, Chandra N, Callahan MM. 2008. Six-day randomized safety trial of intravaginal lime juice. J Acquir Immune Defic Syndr 49:243-250. http://dx.doi.org/10.1097/QAI.0b013e318186eae7.
46. Schwartz JL, Mauck C, Lai JJ, Creinin MD, Brache V, Ballagh SA, Weiner DH, Hillier SL, Fichorova RN, Callahan M. 2006. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind phase I safety study. Contraception 74:133-140. http://dx.doi.org/10.1016/j.contraception.2006.02.008.
47. Dezzutti CS, Hendrix CW, Marrazzo JM, Pan Z, Wang L, Louissaint N, Kalyoussef S, Torres NM, Hladik F, Parikh U, Mellors J, Hillier SL, Herold BC. 2011. Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators. PLoS One 6:e23136. http://dx.doi.org/10.1371/journal.pone.0023136.
48. van de Wijgert JH, Morrison CS, Cornelisse PG, Munjoma M, Moncada J, Awio P, Wang J, Van der Pol B, Chipato T, Salata RA, Padian NS. 2008. Bacterial vaginosis and vaginal yeast, but not vaginal cleansing, increase HIV-1 acquisition in African women. J Acquir Immune Defic Syndr 48:203-210. http://dx.doi.org/10.1097/QAI.0b013e3181743936.
49. Huppert JS, Huang B, Chen C, Dawood HY, Fichorova RN. 2013. Clinical evidence for the role of Trichomonas vaginalis in regulation of secretory leukocyte protease inhibitor in the female genital tract. J Infect Dis 207:1462-1470. http://dx.doi.org/10.1093/infdis/jit039.
50. Africander D, Louw R, Verhoog N, Noeth D, Hapgood JP. 2011. Differential regulation of endogenous pro-inflammatory cytokine genes by medroxyprogesterone acetate and norethisterone acetate in cell lines of the female genital tract. Contraception 84:423-435. http://dx.doi.org/10.1016/j.contraception.2011.06.006.
51. Patel MV, Fahey JV, Rossoll RM, Wira CR. 2013. Innate immunity in the vagina. Part I. Estradiol inhibits HBD2 and elafin secretion by human vaginal epithelial cells. Am J Reprod Immunol 69:463-474. http://dx.doi.org/10.1111/aji.12078.
52. Africander DJ, Storbeck KH, Hapgood JP. 2014. A comparative study of the androgenic properties of progesterone and the progestins, medroxyprogesterone acetate (MPA) and norethisterone acetate (NET-A). J Steroid Biochem Mol Biol 143:404-415. http://dx.doi.org/10.1016/j.jsbmb.2014.05.007.
53. Bamberger CM, Else T, Bamberger AM, Beil FU, Schulte HM. 1999. Dissociative glucocorticoid activity of medroxyprogesterone acetate in normal human lymphocytes. J Clin Endocrinol Metab 84:4055-4061. http://dx.doi.org/10.1210/jcem.84.11.6091.
54. Africander D, Louw R, Hapgood JP. 2013. Investigating the antimineralocorticoid properties of synthetic progestins used in hormone therapy. Biochem Biophys Res Commun 433:305-310. http://dx.doi.org/10.1016/j.bbrc.2013.02.086.
55. Louw-du Toit R, Hapgood JP, Africander D. 2014. Medroxyprogesterone acetate differentially regulates interleukin (IL)-12 and IL-10 in a human ectocervical epithelial cell line in a glucocorticoid receptor (GR)-dependent manner. J Biol Chem 289:31136-31149. http://dx.doi.org/10.1074/jbc.M114.587311.
56. Govender Y, Avenant C, Verhoog NJ, Ray RM, Grantham NJ, Africander D, Hapgood JP. 2014. The injectable-only contraceptive medroxyprogesterone acetate, unlike norethisterone acetate and progesterone, regulates inflammatory genes in endocervical cells via the glucocorticoid receptor. PLoS One 9:e96497. http://dx.doi.org/10.1371/ journal.pone.0096497.
57. Koubovec D, Vanden Berghe W, Vermeulen L, Haegeman G, Hapgood JP. 2004. Medroxyprogesterone acetate downregulates cytokine gene expression in mouse fibroblast cells. Mol Cell Endocrinol 221:75-85. http://dx.doi.org/10.1016/j.mce.2004.03.006.
58. Mauck C. Assessing markers of inflammation after vaginal product use: nonoxynol-9, cellulose sulfate, and HEC placebo comparative doubleblind phase I trial. Microbicides 2010, Pittsburgh, PA.
59. Karim SA, Karim QA. 2012. 6th N’Galy-Mann lecture: CAPRISA: partnering for scientific innovation in HIV prevention and treatment- opening session. In CROI2012. Seattle. http://retroconference.org/static/ webcasts/2012/.
60. Naranbhai V, Abdool Karim SS, Altfeld M, Samsunder N, Durgiah R, Sibeko S, Abdool Karim Q, Carr WH, CAPRISA004 TRAPS Team. 2012. Innate immune activation enhances HIV acquisition in women, diminishing the effectiveness of tenofovir microbicide gel. J Infect Dis 206:993-1001. http://dx.doi.org/10.1093/infdis/jis465.
61. Bebell LM, Passmore JA, Williamson C, Mlisana K, Iriogbe I, van Loggerenberg F, Karim QA, Karim SA. 2008. Relationship between levels of inflammatory cytokines in the genital tract and CD4+ cell counts in women with acute HIV-1 infection. J Infect Dis 198:710-714. http:// dx.doi.org/10.1086/590503.
62. van de Wijgert JH, Verwijs MC, Turner AN, Morrison CS. 2013. Hormonal contraception decreases bacterial vaginosis but oral contraception may increase candidiasis: implications for HIV transmission. AIDS 27:2141-2153. http://dx.doi.org/10.1097/QAD.0b013e32836290b6.
63. Xu L, Dong B, Wang H, Zeng Z, Liu W, Chen N, Chen J, Yang J, Li D, Duan Y. 2013. Progesterone suppresses Th17 cell responses, and enhances the development of regulatory T cells, through thymic stromal lymphopoietin-dependent mechanisms in experimental gonococcal genital tract infection. Microbes Infect 15:796-805. http://dx.doi.org/10.1016/j.micinf.2013.06.012.
64. Lasarte S, Elsner D, Guía-González M, Ramos-Medina R, Sánchez-Ramón S, Esponda P, Muñoz-Fernández MA, Relloso M. 2013. Female sex hormones regulate the Th17 immune response to sperm and Candida albicans. Hum Reprod 28:3283-3291. http://dx.doi.org/10.1093/humrep/ det348.
65. Vylkova S, Nayyar N, Li W, Edgerton M. 2007. Human β-defensins kill Candida albicans in an energy-dependent and salt-sensitive manner without causing membrane disruption. Antimicrob Agents Chemother 51: 154-161. http://dx.doi.org/10.1128/AAC.00478-06.
66. Morrison C, Fichorova RN, Mauck C, Chen PL, Kwok C, Chipato T, Salata R, Doncel GF. 2014. Cervical inflammation and immunity associated with hormonal contraception, pregnancy and HIV-1 seroconversion. J Acquir Immune Defic Syndr 66:109-117. http://dx.doi.org/10.1097/QAI.0000000000000103.
67. Morrison C, Fichorova RN, Mauck C, Chen PL, Kwok C, Chipato T, Salata R, Doncel GF. 2014. Cervical inflammation and immunity associated with hormonal contraception, pregnancy and HIV-1 seroconversion. J Acquir Immune Defic Syndr 66:109-117. http://dx.doi.org/10.1097/QAI.0000000000000103.
68. Fichorova RN, Richardson-Harman N, Alfano M, Belec L, Carbonneil C, Chen S, Cosentino L, Curtis K, Dezzutti CS, Donoval B, Doncel GF, Donaghay M, Grivel JC, Guzman E, Hayes M, Herold B, Hillier S, Lackman-Smith C, Landay A, Margolis L. 2008. Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal Chem 80: 4741-4751. http://dx.doi.org/10.1021/ac702628q.
69. McElrath TF, Fichorova RN, Allred EN, Hecht JL, Ismail MA, Yuan H, Leviton A, ELGAN Study Investigators. 2011. Blood protein profiles of infants born before 28 weeks differ by pregnancy complication. Am J Obstet Gynecol 204:418.e1-418e12. http://dx.doi.org/10.1016/ j.ajog.2010.12.010.
70. Leviton A, Kuban KC, Allred EN, Fichorova RN, O’Shea TM, Paneth N, ELGAN Study Investigators. 2011. Early postnatal blood concentrations of inflammation-related proteins and microcephaly two years later in infants born before the 28th post-menstrual week. Early Hum Dev 87: 325-330. http://dx.doi.org/10.1016/j.earlhumdev.2011.01.043.
71. Leviton A, Kuban K, O’Shea TM, Paneth N, Fichorova R, Allred EN, Dammann O. 2011. The relationship between early concentrations of 25 blood proteins and cerebral white matter injury in preterm newborns: the ELGAN study. J Pediatr 158:897-903.e1-5. http://dx.doi.org/10.1016/j.jpeds.2010.11.059.
72. Leviton A, Hecht JL, Allred EN, Yamamoto H, Fichorova RN, Dammann O, ELGAN Study Investigators. 2011. Persistence after birth of systemic inflammation associated with umbilical cord inflammation. J Reprod Immunol 90:235-243. http://dx.doi.org/10.1016/j.jri.2011.03.009.
73. Leviton A, Fichorova R, Yamamoto Y, Allred EN, Dammann O, Hecht J, Kuban K, McElrath T, O’Shea TM, Paneth N. 2011. Inflammationrelated proteins in the blood of extremely low gestational age newborns. The contribution of inflammation to the appearance of developmental regulation. Cytokine 53:66-73. http://dx.doi.org/10.1016/j.cyto.2010.09.003.
74. Leviton A, Allred EN, Kuban KC, Dammann O, Fichorova RN, O’Shea TM, Paneth N, ELGAN Study Co-Investigators. 2011. Blood protein concentrations in the first two postnatal weeks associated with early postnatal blood gas derangements among infants born before the 28th week of gestation. The ELGAN Study. Cytokine 56:392-398.
75. Hecht JL, Fichorova RN, Tang VF, Allred EN, McElrath TF, Leviton A, ELGAN Study Investigators. 2011. Relationship between neonatal blood protein concentrations and placenta histologic characteristics in extremely low GA newborns. Pediatr Res 69:68-73. http://dx.doi.org/10.1203/PDR.0b013e3181fed334.
76. Fichorova RN, Onderdonk AB, Yamamoto H, Delaney ML, DuBois AM, Allred E, Leviton A, Extremely Low Gestation Age Newborns (ELGAN) Study Investigators. 2011. Maternal microbe-specific modulation of inflammatory response in extremely low-gestational-age newborns. mBio 2(1):e00280-10. http://dx.doi.org/10.1128/mBio.00280-10.
77. Faupel-Badger JM, Fichorova RN, Allred EN, Hecht JL, Dammann O, Leviton A, McElrath TF. 2011. Cluster analysis of placental inflammatory proteins can distinguish preeclampsia from preterm labor and premature membrane rupture in singleton deliveries less than 28 weeks of gestation. Am J Reprod Immunol 66:488-494. http://dx.doi.org/10.1111/j.1600-0897.2011.01023.x.
78. Bose C, Laughon M, Allred EN, Van Marter LJ, O’Shea TM, Ehrenkranz RA, Fichorova R, Leviton A, ELGAN Study Investigators. 2011. Blood protein concentrations in the first two postnatal weeks that predict bronchopulmonary dysplasia among infants born before the 28th week of gestation. Pediatr Res 69:347-353. http://dx.doi.org/10.1203/PDR.0b013e31820a58f3.
79. Levine M, Ensom MH. 2001. Post hoc power analysis: an idea whose time has passed? Pharmacotherapy 21:405-409. http://dx.doi.org/10.1592/phco.21.5.405.34503.